Agreements reached under this partnership
Business Alliance- 1
Using WEIPU's domestic sales and customer network in China, provide clinical-use cell products, including StemRNA clinical-use iPS cells manufactured using REPROCELL's proprietary RNA reprogramming technology and iPSC-derived mesenchymal stem cells (iMSCs)
- 2
Develop a comprehensive solution in the Chinese market that includes StemEdit clinical-use gene-editing services, based on REPROCELL's proprietary gene-editing platform, as well as manufacturing services for master cell banks (MCBs) and working cell banks (WCBs), which are essential for the development of cell therapy products
- 3
WEIPU will provide biological testing, safety evaluation, and cell bank characterization services
- 4
Establish an integrated service framework to support cell therapy developers in China from the early stages of development through the clinical development stage
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The impact of this matter on results for the current fiscal year is currently expected to be minor, but over the medium to long term, it is expected to make a significant contribution to REPROCELL's further growth and the sustainable enhancement of its corporate value.
| Item | Details |
|---|---|
| Name of alliance partner | 微谱生物科技有限公司 (WEIPU Biotechnology Co., Ltd.) |
| Alliance partner's business activities | A CRTO (Contract Research and Testing Organization) providing biological testing, safety evaluation, and cell bank characterization services to companies in the biopharmaceutical, cell therapy, medical device, and chemical sectors |
| Alliance partner's location | Suzhou, Jiangsu Province, China |
| Type of alliance | Business Alliance |
| Details of the alliance | Using WEIPU's domestic sales and customer network in China, provide clinical-use cell products, including StemRNA clinical-use iPS cells manufactured using REPROCELL's proprietary RNA reprogramming technology and iPSC-derived mesenchymal stem cells (iMSCs), Develop a comprehensive solution in the Chinese market that includes StemEdit clinical-use gene-editing services, based on REPROCELL's proprietary gene-editing platform, as well as manufacturing services for master cell banks (MCBs) and working cell banks (WCBs), which are essential for the development of cell therapy products, WEIPU will provide biological testing, safety evaluation, and cell bank characterization services, Establish an integrated service framework to support cell therapy developers in China from the early stages of development through the clinical development stage |
| Impact on Business Performance | The impact of this matter on results for the current fiscal year is currently expected to be minor, but over the medium to long term, it is expected to make a significant contribution to REPROCELL's further growth and the sustainable enhancement of its corporate value. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.China's regenerative medicine and cell therapy sectors are growing, with investment in research and development and clinical applications expanding. By combining WEIPU's sales and customer network and testing and evaluation services with REPROCELL's clinical-use cell products and related services, the parties will accelerate business development in the Chinese market.